SpringerLink
Log in

Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Introduction

Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the treatment of psoriatic arthritis (PsA). Despite this, their discontinuation due to inefficacy or adverse events is often observed. The aims of this study are to describe retention rates and treatment trends of anti-TNFα, anti-IL17, and anti-IL12/23R agents in patients with PsA and to identify factors associated with bDMARDs discontinuation in a real-world clinical setting.

Methods

A retrospective cohort study based on the analysis of the three Italian prescription cohorts of patients with PsA has been performed. Survival analysis was performed using Kaplan-Meier curves and Cox proportional-hazards model.

Results

During the follow up, which lasted 25.5 (12–60) months, 68 patients discontinued a bDMARD: 13 for primary failure, 12 for secondary failure, 15 for adverse events, 5 for remission, 12 because of lost at follow-up, and 11 for other causes. Cox proportional-hazards demonstrated that a shorter disease duration (HR 0.994991, 95% CI 0.9910336–0.9989647, p = 0.014) and first-line bDMARD (HR 0.5090986, 95% CI 0.3073519–0.8432722, p = 0.009) have a protective role on bDMARD retention rate, while the multivariable analysis failed in demonstrating an independent protective role of male sex on drug retention rate (p = 0.083). No significant differences in retention rate have been found regarding biologic drugs, combination therapy or monotherapy, and class of bDMARD (anti-TNFα or anti-pIL12/23R and anti-IL-17).

Conclusions

This study shows that a shorter disease duration and treatment with a first-line bDMARD are predictors of bDMARDs retention rate, further highlighting the importance of early diagnosis of PsA.

Key Points

• No significant difference in retention among patients treated with anti-IL17A, anti-IL12/23R, and anti-TNFα agents has been demonstrated.

• A shorter disease duration and first-line bDMARD treatment are associated with persistence in biologic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D'Angelo S, Mathieu A, Cauli A, Punzi L, Ramonda R, Scarpa R, Maccarone M, Lubrano E (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35(6):991–1010

    PubMed  Google Scholar 

  2. Napolitano M, Caso F, Scarpa R, Megna M, Patri A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35(8):1893–1901. https://doi.org/10.1007/s10067-016-3295-9

    Article  PubMed  Google Scholar 

  3. Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus 3:759. https://doi.org/10.1186/2193-1801-3-759

    Article  PubMed  PubMed Central  Google Scholar 

  4. Caso F, Costa L, Del Puente A, Di Minno MN, Lupoli G, Scarpa R, Peluso R (2015) Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis 6(6):328–338. https://doi.org/10.1177/2040622315608647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L, Balato N, Scarpa R (2018) Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol 37(7):1739–1741. https://doi.org/10.1007/s10067-018-4090-6

    Article  PubMed  Google Scholar 

  6. Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12(3):315–331. https://doi.org/10.1586/1744666x.2016.1117941

    Article  CAS  PubMed  Google Scholar 

  7. Caso F, Costa L, Del Puente A, Scarpa R (2015) Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther 15(1):1–2. https://doi.org/10.1517/14712598.2015.973398

    Article  CAS  PubMed  Google Scholar 

  8. Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Exp Opin Emerg Drugs 21(1):69–79. https://doi.org/10.1517/14728214.2016.1146679

    Article  CAS  Google Scholar 

  9. Atzeni F, Costa L, Caso F, Scarpa R, Sarzi-Puttini P (2015) Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis. J Rheumatol Suppl 93:79–81. https://doi.org/10.3899/jrheum.150643

    Article  CAS  PubMed  Google Scholar 

  10. Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM (2013) Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 14(17):2311–2313. https://doi.org/10.1517/14656566.2013.840292

    Article  CAS  PubMed  Google Scholar 

  11. Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F (2017) Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 18(15):1557–1567. https://doi.org/10.1080/14656566.2017.1378343

    Article  CAS  PubMed  Google Scholar 

  12. Chiricozzi A, Saraceno R, Novelli L, Fida M, Caso F, Scarpa R, Costa L, Perricone R, Romanelli M, Chimenti S, Chimenti MS (2016) Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015). Exp Opin Ther Pat 26(7):757–766. https://doi.org/10.1080/13543776.2016.1192129

    Article  CAS  Google Scholar 

  13. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ) 68(5):1060–1071. https://doi.org/10.1002/art.39573

    Article  Google Scholar 

  14. Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 12(12):743–750. https://doi.org/10.1038/nrrheum.2016.183

    Article  PubMed  Google Scholar 

  15. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510. https://doi.org/10.1136/annrheumdis-2015-208337

    Article  CAS  PubMed  Google Scholar 

  16. Costa L, Lubrano E, Ramonda R, Chimenti MS, Vezzu M, Perrotta FM, Del Puente A, Peluso R, Bottiglieri P, Lorenzin M, Sunzini F, Darda MA, Fiocco U, Perricone R, Punzi L, Scarpa R, Caso F (2017) Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clin Rheumatol 36(8):1797–1802. https://doi.org/10.1007/s10067-017-3697-3

    Article  PubMed  Google Scholar 

  17. Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, Lubrano E, Peluso R, Caso P, Galeazzi M, Punzi L, Scarpa R, Costa L (2015) Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 15(5):641–650. https://doi.org/10.1517/14712598.2015.1011616

    Article  CAS  PubMed  Google Scholar 

  18. Costa L, Caso F, Del Puente A, Di Minno MN, Peluso R, Scarpa R (2016) Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol 43(12):2149–2154. https://doi.org/10.3899/jrheum.160542

    Article  PubMed  Google Scholar 

  19. Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33(4):543–547. https://doi.org/10.1007/s10067-014-2536-z

    Article  PubMed  PubMed Central  Google Scholar 

  20. Napolitano M, Costa L, Caso F, Megna M, Scarpa R, Balato N, Ayala F, Balato A (2017) Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol 36(7):1589–1593. https://doi.org/10.1007/s10067-017-3700-z

    Article  PubMed  Google Scholar 

  21. Chimenti MS, Ortolan A, Lorenzin M, Triggianese P, Talamonti M, Costa L, Caso F, Favero M, Teoli M, Galluzzo M, Scarpa R, Punzi L, Perricone R, Ramonda R (2018) Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol 37(2):397–405. https://doi.org/10.1007/s10067-017-3953-6

    Article  PubMed  Google Scholar 

  22. Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R&D 17(4):509–522. https://doi.org/10.1007/s40268-017-0215-7

    Article  CAS  Google Scholar 

  23. Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483–1503. https://doi.org/10.2147/PPA.S167508

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD open 1(1):e000181–e000181. https://doi.org/10.1136/rmdopen-2015-000181

    Article  PubMed  PubMed Central  Google Scholar 

  25. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I (2011) Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 29(3 Suppl 66):S28–S41

    PubMed  Google Scholar 

  26. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53. https://doi.org/10.1136/ard.2008.102053

    Article  CAS  PubMed  Google Scholar 

  27. Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, Gomez-Reino JJ (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509–515. https://doi.org/10.1007/s00296-018-4177-z

    Article  CAS  PubMed  Google Scholar 

  28. Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL (2017) Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol 36(8):1747–1755. https://doi.org/10.1007/s10067-017-3712-8

    Article  PubMed  Google Scholar 

  29. Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S, Galeazzi M (2014) Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediat Inflamm 2014:862969. https://doi.org/10.1155/2014/862969

    Article  CAS  Google Scholar 

  30. Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL (2017) Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken) 69(6):867–874. https://doi.org/10.1002/acr.23090

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Luca Navarini and Luisa Costa contributed equally to this work.

Authors and Affiliations

  1. Unit of Allergology, Clinical Immunology and Rheumatology, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy

    Luca Navarini, Damiano Currado, Domenico Paolo Emanuele Margiotta & Antonella Afeltra

  2. Rheumatology Unit, Department of Clinical Medicine and Surgery, School of Medicine, University of Naples Federico II, Naples, Italy

    Luisa Costa, Marco Tasso, Carolina Benigno, Raffaele Scarpa & Francesco Caso

  3. Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, Italy

    Maria Sole Chimenti, Giulia Lavinia Fonti, Erica De Martino & Roberto Perricone

  4. Unit of Clinical Laboratory Science, Department of Medicine, Campus Bio-Medico of Rome University, Rome, Italy

    Massimo Ciccozzi

Authors
  1. Luca Navarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luisa Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Tasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Sole Chimenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Damiano Currado
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giulia Lavinia Fonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Massimo Ciccozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Domenico Paolo Emanuele Margiotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carolina Benigno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Erica De Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Roberto Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Antonella Afeltra
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Raffaele Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Francesco Caso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Navarini.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Navarini, L., Costa, L., Tasso, M. et al. Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clin Rheumatol 39, 2663–2670 (2020). https://doi.org/10.1007/s10067-020-05027-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05027-1

Keywords

Search

Navigation